| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Tiago Reis Marques, Sridhar Natesan, Flavia Niccolini, Marios Politis, Roger N Gunn, Graham E Searle, Oliver Howes, Eugenii A Rabiner, Shitij Kapu. Phosphodiesterase 10A in Schizophrenia: A PET Study Using [(11)C]IMA107. The American journal of psychiatry. vol 173. issue 7. 2017-04-28. PMID:26892941. |
using a newly developed and validated radioligand, [(11)c]ima107, the authors report the first in vivo assessment of pde10a brain expression in patients with schizophrenia. |
2017-04-28 |
2023-08-13 |
Not clear |
| A K Halder, S A Amin, T Jha, S Gaye. Insight into the structural requirements of pyrimidine-based phosphodiesterase 10A (PDE10A) inhibitors by multiple validated 3D QSAR approaches. SAR and QSAR in environmental research. vol 28. issue 3. 2017-04-17. PMID:28322591. |
the over-expression of phosphodiesterase 10a (pde10a) enzyme may be a potential target for schizophrenia and huntington's disease. |
2017-04-17 |
2023-08-13 |
Not clear |
| Courtney M MacMullen, Mohammad Fallahi, Ronald L Davi. Novel PDE10A transcript diversity in the human striatum: Insights into gene complexity, conservation and regulation. Gene. vol 606. 2017-01-27. PMID:28042091. |
dysregulation of camp signaling has been proposed as a cause of bipolar disorder and pde10a inhibitors have been investigated as potential therapeutics for schizophrenia. |
2017-01-27 |
2023-08-13 |
human |
| Akihiro Takano, Vladimir Stepanov, Ryuji Nakao, Nahid Amini, Balázs Gulyás, Haruhide Kimura, Christer Halldi. Brain PET measurement of PDE10A occupancy by TAK-063, a new PDE10A inhibitor, using [11 C]T-773 in nonhuman primates. Synapse (New York, N.Y.). vol 70. issue 6. 2017-01-09. PMID:26878349. |
because phosphodiesterase 10a (pde10a) degrades both cyclic adenosine monophosphate and cyclic guanosine monophosphate and is distributed mainly in the striatum, pde10a inhibitors have been considered to potentially be useful therapeutic agents for psychiatric and neurodegenerative diseases such as schizophrenia and huntington's disease. |
2017-01-09 |
2023-08-13 |
monkey |
| Renee C Gentzel, Dawn Toolan, Rhonda Roberts, Amy Jo Koser, Monika Kandebo, James Hershey, John J Renger, Jason Uslaner, Sean M Smit. The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents. Neuropharmacology. vol 99. 2016-08-30. PMID:26044638. |
phosphodiesterase 10a (pde10a) has garnered attention as a potential therapeutic target for schizophrenia due to its prominent striatal expression and ability to modulate striatal signaling. |
2016-08-30 |
2023-08-13 |
rat |
| Christopher D Cox, Eric D Hostetler, Broc A Flores, Jeffrey L Evelhoch, Hong Fan, Liza Gantert, Marie Holahan, Waisi Eng, Aniket Joshi, Georgia McGaughey, Xiangjun Meng, Mona Purcell, Izzat T Raheem, Kerry Riffel, Youwei Yan, John J Renger, Sean M Smith, Paul J Colema. Discovery of [¹¹C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors. Bioorganic & medicinal chemistry letters. vol 25. issue 21. 2016-06-20. PMID:26077491. |
phosphodiesterase 10a (pde10a) inhibition has recently been identified as a potential mechanism to treat multiple symptoms that manifest in schizophrenia. |
2016-06-20 |
2023-08-13 |
rat |
| Miklós Tóth, Jenny Häggkvist, Vladimir Stepanov, Akihiro Takano, Ryuji Nakao, Nahid Amini, Shotaro Miura, Haruhide Kimura, Takahiko Taniguchi, Balázs Gulyás, Christer Halldi. Molecular Imaging of PDE10A Knockout Mice with a Novel PET Radiotracer: [(11)C]T-773. Molecular imaging and biology. vol 17. issue 4. 2016-04-01. PMID:25622810. |
pde10a is associated with parkinson's disease and different neuropsychiatric disorders such as huntington's disease, obsessive-compulsive disorders (ocd) and schizophrenia. |
2016-04-01 |
2023-08-13 |
mouse |
| Junfeng Li, Xiang Zhang, Hongjun Jin, Jinda Fan, Hubert Flores, Joel S Perlmutter, Zhude T. Synthesis of Fluorine-Containing Phosphodiesterase 10A (PDE10A) Inhibitors and the In Vivo Evaluation of F-18 Labeled PDE10A PET Tracers in Rodent and Nonhuman Primate. Journal of medicinal chemistry. vol 58. issue 21. 2016-02-25. PMID:26430878. |
these results suggest this strategy may identify a (18)f-labeled pet tracer for quantifying the levels of pde10a in patients with cns disorders including huntington's disease and schizophrenia. |
2016-02-25 |
2023-08-13 |
rat |
| Akina Harada, Kazunori Suzuki, Naomi Kamiguchi, Maki Miyamoto, Kimio Tohyama, Kosuke Nakashima, Takahiko Taniguchi, Haruhide Kimur. Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor. PloS one. vol 10. issue 3. 2016-02-23. PMID:25815469. |
phosphodiesterase 10a (pde10a) inhibition is a novel and promising approach for the treatment of central nervous system disorders such as schizophrenia and huntington's disease. |
2016-02-23 |
2023-08-13 |
mouse |
| Akina Harada, Kazunori Suzuki, Shotaro Miura, Tomoaki Hasui, Naomi Kamiguchi, Tsuyoshi Ishii, Takahiko Taniguchi, Takanobu Kuroita, Akihiro Takano, Vladimir Stepanov, Christer Halldin, Haruhide Kimur. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A. Nuclear medicine and biology. vol 42. issue 2. 2015-09-08. PMID:25451212. |
recent studies have suggested that pde10a inhibition is a novel approach for the treatment of disorders such as schizophrenia and huntington's disease. |
2015-09-08 |
2023-08-13 |
monkey |
| Lindsay S Wilson, Nicholas J Brando. Emerging biology of PDE10A. Current pharmaceutical design. vol 21. issue 3. 2015-07-28. PMID:25159072. |
one pde family, pde10a, is highly enriched in the brain and its unique expression profile in specific brain regions of interest, in particular to antipsychotic treatment, has made it an attractive therapeutic target for the treatment of schizophrenia. |
2015-07-28 |
2023-08-13 |
Not clear |
| Hang Chen, Dianna Lester-Zeiner, Jianxia Shi, Silke Miller, Charlie Glaus, Essa Hu, Ning Chen, Jessica Able, Christopher Biorn, Jamie Wong, Ji Ma, Klaus Michelsen, Geraldine Hill Della Puppa, Tim Kazules, Hui Hannah Dou, Santosh Talreja, Xiaoning Zhao, Ada Chen, Shannon Rumfelt, Roxanne K Kunz, Hu Ye, Oliver R Thiel, Toni Williamson, Carl Davis, Amy Porter, David Immke, Jennifer R Allen, James Treano. AMG 580: a novel small molecule phosphodiesterase 10A (PDE10A) positron emission tomography tracer. The Journal of pharmacology and experimental therapeutics. vol 352. issue 2. 2015-07-08. PMID:25502803. |
phosphodiesterase 10a (pde10a) inhibitors have therapeutic potential for the treatment of psychiatric and neurologic disorders, such as schizophrenia and huntington's disease. |
2015-07-08 |
2023-08-13 |
human |
| José Manuel Bartolomé-Nebreda, Sergio A Alonso de Diego, Marta Artola, Francisca Delgado, Óscar Delgado, María Luz Martín-Martín, Carlos M Martínez-Viturro, Miguel Ángel Pena, Han Min Tong, Michiel Van Gool, José Manuel Alonso, Alberto Fontana, Gregor J Macdonald, Anton Megens, Xavier Langlois, Marijke Somers, Greet Vanhoof, Susana Conde-Ceid. Identification of a novel orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor with efficacy in animal models of schizophrenia. Journal of medicinal chemistry. vol 58. issue 2. 2015-03-31. PMID:25495129. |
identification of a novel orally bioavailable phosphodiesterase 10a (pde10a) inhibitor with efficacy in animal models of schizophrenia. |
2015-03-31 |
2023-08-13 |
Not clear |
| Jodi E Gresack, Patricia A Seymour, Christopher J Schmidt, Victoria B Risbroug. Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating. Psychopharmacology. vol 231. issue 10. 2015-02-21. PMID:24363077. |
the ability of such agents to act to potentiate d1 receptor signaling while inhibiting d2 receptor signaling suggest that pde10a inhibitors may have a unique antipsychotic-like behavioral profile differentiated from the d2 receptor antagonist-specific antipsychotics currently used in the treatment of schizophrenia. |
2015-02-21 |
2023-08-12 |
Not clear |
| Chanchal Mondal, Amit Kumar Halder, Nilanjan Adhikari, Tarun Jh. Structural findings of cinnolines as anti-schizophrenic PDE10A inhibitors through comparative chemometric modeling. Molecular diversity. vol 18. issue 3. 2015-02-04. PMID:24789056. |
phosphodiesterase10a (pde10a) enzyme plays crucial role in cellular signaling pathways in schizophrenia. |
2015-02-04 |
2023-08-13 |
Not clear |
| A M García, M Redondo, A Martinez, C Gi. Phosphodiesterase 10 inhibitors: new disease modifying drugs for Parkinson's disease? Current medicinal chemistry. vol 21. issue 10. 2014-11-10. PMID:24372206. |
basal ganglia dysfunction is associated with neuropsychiatric disorders and until recently the development of pde10a inhibitors has been focused on schizophrenia. |
2014-11-10 |
2023-08-12 |
Not clear |
| Subramaniam Uthayathas, Gunasingh J Masilamoni, Christopher L Shaffer, Christopher J Schmidt, Frank S Menniti, Stella M Pap. Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications. Neuropharmacology. vol 77. 2014-08-26. PMID:24490227. |
these findings have supported the clinical investigation of pde10a inhibitors as a new treatment for schizophrenia. |
2014-08-26 |
2023-08-12 |
monkey |
| Andrea R Nawrocki, Carlos G Rodriguez, Dawn M Toolan, Olga Price, Melanie Henry, Gail Forrest, Daphne Szeto, Carol Ann Keohane, Yie Pan, Karen M Smith, Izzat T Raheem, Christopher D Cox, Joyce Hwa, John J Renger, Sean M Smit. Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance. Diabetes. vol 63. issue 1. 2014-02-24. PMID:24101672. |
phosphodiesterase 10a (pde10a) is a novel therapeutic target for the treatment of schizophrenia. |
2014-02-24 |
2023-08-12 |
mouse |
| Andrea R Nawrocki, Carlos G Rodriguez, Dawn M Toolan, Olga Price, Melanie Henry, Gail Forrest, Daphne Szeto, Carol Ann Keohane, Yie Pan, Karen M Smith, Izzat T Raheem, Christopher D Cox, Joyce Hwa, John J Renger, Sean M Smit. Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance. Diabetes. vol 63. issue 1. 2014-02-24. PMID:24101672. |
these data demonstrate that pde10a inhibition represents a novel antipsychotic target that may have additional metabolic benefits over current medications for schizophrenia by suppressing food intake, alleviating weight gain, and reducing the risk for the development of diabetes. |
2014-02-24 |
2023-08-12 |
mouse |
| Koen Van Laere, Rawaha U Ahmad, Hendra Hudyana, Kristof Dubois, Mark E Schmidt, Sofie Celen, Guy Bormans, Michel Kool. Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brain. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. vol 54. issue 8. 2013-10-21. PMID:23843566. |
phosphodiesterase 10a (pde10a) plays a central role in striatal signaling and is implicated in several neuropsychiatric disorders, such as movement disorders and schizophrenia. |
2013-10-21 |
2023-08-12 |
human |